Chitosan reduces plasma adipocytokines and lipid accumulation in liver and adipose tissues and ameliorates insulin resistance in diabetic rats

J Med Food. 2012 May;15(5):453-60. doi: 10.1089/jmf.2011.1882. Epub 2012 Mar 22.

Abstract

Chitosan is a natural product derived from chitin. To investigate the hypoglycemic and anti-obesity effects of chitosan, male Sprague-Dawley rats were divided into four groups: normal control, diabetic, and diabetic fed 5% or 7% chitosan. Diabetes was induced in rats by injecting streptozotocin/nicotinamide. After 10 weeks of feeding, the elevated plasma glucose, tumor necrosis factor-α, and interleukin-6 and lower adiponetin levels caused by diabetes were effectively reversed by chitosan treatment. In addition, 7% chitosan feeding also elevated plasma glucagon-like peptide-1 levels and lowered the insulin resistance index (homeostasis model assessment) in diabetic rats. Lower adipocyte granular intensities and higher lipolysis rates in adipose tissues were noted in the 7% chitosan group. Moreover, chitosan feeding reduced hepatic triglyceride and cholesterol contents and increased hepatic peroxisomal proliferator-activated receptor α expression in diabetic rats. Our results indicate that long-term administration of chitosan may reduce insulin resistance through suppression of lipid accumulation in liver and adipose tissues and amelioration of chronic inflammation in diabetic rats.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adiponectin / blood*
  • Adipose Tissue / cytology
  • Adipose Tissue / drug effects*
  • Adipose Tissue / metabolism
  • Animals
  • Biological Products / pharmacology
  • Biological Products / therapeutic use
  • Blood Glucose / metabolism
  • Chitosan / pharmacology
  • Chitosan / therapeutic use*
  • Cholesterol / metabolism
  • Diabetes Mellitus, Experimental / drug therapy*
  • Diabetes Mellitus, Experimental / metabolism
  • Glucagon-Like Peptide 1 / blood
  • Hypoglycemic Agents / pharmacology
  • Hypoglycemic Agents / therapeutic use
  • Inflammation / drug therapy
  • Inflammation / metabolism
  • Insulin / metabolism
  • Insulin Resistance*
  • Interleukin-6 / blood
  • Lipid Metabolism / drug effects*
  • Liver / drug effects*
  • Liver / metabolism
  • Male
  • PPAR alpha / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Triglycerides / metabolism
  • Tumor Necrosis Factor-alpha / blood

Substances

  • Adiponectin
  • Biological Products
  • Blood Glucose
  • Hypoglycemic Agents
  • Insulin
  • Interleukin-6
  • PPAR alpha
  • Triglycerides
  • Tumor Necrosis Factor-alpha
  • Glucagon-Like Peptide 1
  • Chitosan
  • Cholesterol